Objectives: Iron regulation is an important modifier of renal ischemiareperfusion injury, but the role of iron-binding proteins during cardiopulmonary bypass remains unclear. The goal was to characterize iron-binding proteins throughout ischemia-reperfusion injury to determine their association with acute kidney injury development.
An improved understanding of the human physiologic responses to renal ischemia-reperfusion injury (IRI) may help develop novel approaches to management. Furthermore, tools that identify incipient renal injury before loss of function may be useful to facilitate early therapeutic intervention for acute kidney injury (AKI) and could be used as an enrichment strategy for clinical trials evaluating novel AKI therapeutics. 1 To facilitate early identification, preoperative clinical risk prediction models have been developed to predict the need for renal replacement therapy after cardiac surgery. 2 The Cleveland Clinic Score (Thakar score) is a well-validated model 3 that predicts AKI and dialysis after cardiac surgery. 4, 5 However, few studies have evaluated intraoperative AKI markers during IRI, and these only reported poor to modest intraoperative discrimination, without demonstrating added value on preoperative clinical prediction. 6 Free iron release is a common consequence of cardiopulmonary bypass (CPB), resulting in increased circulating iron and oxidative stress. 7 Iron regulatory pathways play a role in the development of postcardiac surgery AKI, [7] [8] [9] and indeed, ferroptosis is a key mediator of IRI-related renal tubular cell death. 10 Markers of these processes, such as plasma catalytic iron and plasma free hemoglobin, are elevated intraoperatively and associated with postoperative AKI development. 7, 11 However, the intraoperative response to free iron release remains incompletely characterized. Neutrophil gelatinaseassociated lipocalin (NGAL) and urine hepcidin-25 are both iron-sequestering proteins associated with human AKI development and are renoprotective when administered in animal models of AKI. 8, 9, [12] [13] [14] [15] [16] However, both NGAL and urine hepcidin-25 peak postoperatively, with only modest intraoperative AKI discrimination (intraoperative urine and plasma NGAL area under the curve [AUC], 0.59 and 0.64, respectively). [15] [16] [17] [18] [19] Because nephrotoxic catalytic iron release occurs during CPB, we hypothesized that an expanded capacity for iron binding or sequestration would be inversely associated with AKI development and may act as early markers of incipient AKI development. Therefore, the goal of this study was to evaluate intraoperative serum ferritin and transferrin saturation during renal IRI to determine their association with AKI development in a prospective observational cohort of adult patients who underwent cardiac surgery.
MATERIALS AND METHODS
The study protocol was approved by the University of Manitoba institutional review board, and all patients provided written informed consent (Ethics Approval HS15221; H2012:097). The funding agency had no role in the study design, data analysis, or manuscript preparation. All elective coronary artery bypass graft (CABG) or valve replacement operations requiring CPB at St Boniface Hospital from June 2012 to October 2014 were considered for inclusion. Exclusion criteria included off-pump surgeries, preexisting dialysis dependence or renal transplant, deceased before surgery, canceled/delayed surgeries, and missed urine or serum bio-banking. Patient demographics and comorbidities were abstracted from patient charts and the Manitoba Cardiac Surgery Database. Intraoperative and postoperative data collection included duration of the operation, total CPB and aortic crossclamp time, urine output, blood pressure, inotrope support, blood products, and potential nephrotoxic exposures (aminoglycoside, nonsteroidal anti-inflammatory agents, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and contrast).
Primary Outcome
Baseline serum creatinine (Cr) was established using an average of the 2 most recent preoperative serum creatinine values for all patients. AKI was defined using the 2012 Kidney Disease Improving Global Outcomes (KDIGO) criteria: serum Cr increase greater than 50% from baseline or 0.3 mg/dL or more increase within 48 hours. 20 The KDIGO urine output criterion was not applied to determine AKI. 21 
Primary Exposure Variables of Interest
The Cleveland Clinic Score, or Thakar score, was used as a base clinical risk prediction model for AKI. 3 Serum samples obtained immediately after the start of CPB and 1-hour CPB (intraoperative) were analyzed for ferritin and transferrin saturation. Intraoperative serum ferritin was measured using the Cobas e601/e602 Roche Analyzer (Basel, Switzerland), iron was measured using the Cobas C702 Roche Analyzer, total iron-binding capacity was measured using the Ortho Vitros 4600 (Raritan, NJ) in the clinical laboratory, and transferrin saturation (%) was calculated. Urine hepcidin-25 at POD 1 was measured with a competitive enzyme-linked immunosorbent assay (Penlab S-1337) (Biotek Synergy 4 microplate reader, Gen 5 software, Fisher Scientific, Waltham, Mass), as previously described. 16, 22 Scanning this QR code will take you to a supplemental tables and video for the article.
Statistical Analyses
All data were analyzed using SAS Version 9.3 (SAS Institute, Inc, Cary, NC). Continuous variables are presented as median (interquartile range) and compared using the Mann-Whitney U test. Categoric variables are presented as frequency (percentage) and compared with the chi-square test. Logistic regression was used to assess the univariate association of patient characteristics with postoperative AKI. Two multivariable logistic regression models of clinical prediction with intraoperative iron-handling biomarkers (intraoperative model and postoperative model) were assessed for their ability to predict postoperative AKI and compared with the base clinical prediction model (Thakar score alone). The intraoperative model included the Thakar score, intraoperative serum ferritin, and transferrin saturation at 1-hour CPB. The postoperative model included the Thakar score, intraoperative serum ferritin, and transferrin saturation at 1-hour CPB, and urine hepcidin-25 at POD 1. We examined the discrimination and goodness-of-fit for each model by calculating the area under the curve (AUC), Hosmer-Lemeshow test, and Akaike information criterion (AIC). The AIC was generated to determine the balance between goodness-of-fit and model complexity and to allow for model quality comparison. Each enriched model was compared with the base clinical model (Thakar score alone) to examine improvement in discrimination (DAUC, integrated discrimination improvement [IDI] ) and reclassification (Net Reclassification Index). Spearman's rank correlation coefficients (r) were calculated between each of the predictor variables. Multicollinearity was assessed using a multiple linear regression model. Two variables were considered highly correlated if jrj was greater than .7 and collinear if the variance inflation factor was more than 10.
RESULTS

Prospective Observational Cohort
A total of 380 adult patients who underwent cardiac surgery were enrolled in the prospective observational cohort. Twenty-one patients were excluded for off-pump surgeries (n ¼ 3), preexisting dialysis dependence (n ¼ 3), deceased before surgery (n ¼ 1), and canceled/delayed surgeries (n ¼ 14). Fifty-eight patients were excluded for missed serum and urine bio-banking, resulting in a final prospective observational cohort of 40 patients with AKI and 261 patients without AKI (n ¼ 301) (Figure 1) . The study population characteristics are reported in Table 1 , and there were no differences in the characteristics of the final study population (n ¼ 301) versus those excluded for missed bio-banking (n ¼ 58) (Table E1 ).
Intraoperative Serum Ferritin Is Inversely Associated With Acute Kidney Injury
Intraoperative serum ferritin and transferrin saturation at the start of CPB and 1-hour CPB were compared in those with and without AKI. Serum ferritin at the start of CPB and 1 hour into CPB was lower in AKI versus non-AKI (P ¼ .005 and P ¼ .001, respectively). Serum transferrin saturation at the start of CPB and 1 hour into CPB was similar in AKI and non-AKI (Figure 2 ).
Univariate Predictors of Acute Kidney Injury
Clinical variables associated with AKI development included preoperative Modified Diet in Renal Disease estimated glomerular filtration rate, baseline Cr, diabetes mellitus, congestive heart failure, higher Thakar score, lower preoperative hemoglobin, and total amount of intraoperative red blood cell (RBC) transfusions (Table 2 ). It is notable that patients without AKI had a higher preoperative Hb (P < .001), and patients without AKI had a higher transfusion requirement (P<.001); these data were significantly correlated (R À0. 41) , suggesting that individuals with lower preoperative Hb were more likely to require blood transfusion. CPB pump time was not a univariate predictor of AKI (P ¼ .094). Intraoperative and postoperative blood pressures and inotrope requirement were not associated with AKI development in this cohort. Only 1 patient received contrast dye postoperatively, and therefore meaningful analysis could not be conducted.
Intraoperative serum ferritin was inversely associated with AKI, with higher levels associated with a lower likelihood of developing AKI (start CPB: odds ratio [OR], 0.62; 95% confidence interval [CI], 0.44-0.86; P ¼ .005; 1-hour CPB: OR, 0.62; 95% CI, 0.45-0.84; P ¼ .002). As previously reported in this cohort, postoperative day (POD) 1 urine hepcidin-25 was inversely associated with AKI development (OR, 0.62; 95% CI, 0.45-0.85; P ¼ .002). 22 Serum transferrin saturation at 1-hour CPB showed only a trend to association with postoperative AKI (P ¼ .07) ( Table 2) .
Iron-Sequestering Proteins Are Multivariable Predictors of Acute Kidney Injury
A preoperative base clinical model using the Thakar score was established for AKI prediction (OR, 1.62; 95% CI, 1.34-1.96; P < .001). The intraoperative model (Thakar score, serum ferritin, and transferrin saturation) demonstrated that serum ferritin and transferrin saturation at 1-hour CPB predicted postoperative AKI, after adjusting for preoperative clinical prediction (serum ferritin OR, 0.66; 95% CI, 0.48-0.91; P ¼ .012 and transferrin saturation OR, 1.26; 95% CI, 1.02-1.55; P ¼ .035) ( Table 3 ). Because sources of free iron from hemolysis may contribute to AKI, total intraoperative RBC transfusions and CPB pump time were added to the intraoperative model, but neither were significant multivariable predictors of AKI (RBC transfusions OR, 1.13; 95% CI, 0.94-1.35; P ¼ .21 and CPB pump time OR, 1.25; 95% CI, 0.85-1.83; P ¼ .26). Preoperative hemoglobin was not a significant multivariable predictor of postoperative AKI development (P ¼ .158). Because different iron-sequestering proteins may be linked by the same causal pathways, we next sought to determine if urine hepcidin-25 was an independent predictor of AKI. The postoperative model (Thakar score, serum ferritin and transferrin saturation, urine hepcidin-25) demonstrated that urine hepcidin-25 remained an independent predictor of AKI (OR, 0.68; 95% CI, 0.48-0.95; P ¼ .026) ( Table 3 Table 4 ). The sensitivities and specificities of intraoperative and postoperative models are presented over a range of cutoffs (Table E2) .
Intraoperative Iron-Sequestering Proteins Improve Preoperative Clinical Prediction
The intraoperative model (Thakar score, serum ferritin, and transferrin saturation) demonstrated improvement on base clinical prediction as measured by the absolute difference in AUC and IDI (P ¼ .011 and P ¼ .011, respectively), but not by Net Reclassification Index (P ¼ .25). Furthermore, the postoperative model (Thakar score, serum ferritin and transferrin saturation, urine hepcidin-25) demonstrated superior model discrimination relative to clinical prediction alone, and by a higher margin than enriched model 1, measured by both absolute difference in AUC and by IDI (DAUC 0.08, 95% CI, 0.03-0.13, P ¼ .002; IDI 0.10, 95% CI, 0.03-0.17, P ¼ .003). The postoperative model was also more likely to correctly reclassify subjects (Net Reclassification Index 0.50, 95% CI, 0.18-0.82, P ¼ .003) ( Table 5) .
Sensitivity Analyses
Because serum ferritin, serum transferrin saturation, and urinary hepcidin-25 are all markers of iron-binding or sequestration, we sought to determine if they were highly correlated. A correlation matrix was generated that demonstrated these variables were not highly correlated and none were collinear. Therefore, no decision was taken to remove any variables from the models (Table E3) .
To identify early predictors of AKI, we excluded patients who developed AKI before the measurement of serum ferritin and transferrin saturation at 1-hour CPB and urine hepcidin-25 at POD 1.
Intraoperative serum Cr was measured in all patients, and no patients developed intraoperative AKI. Six patients developed KDIGO AKI before POD 1; therefore, the multivariable analysis for the postoperative model was repeated on adjusted prospective observational cohort (n ¼ 295). Serum ferritin and urine hepcidin-25 remained independent predictors of postoperative AKI; however, serum transferrin saturation did not. The overall model still showed good AKI prediction with AUC 0.81 (0.73-0.87) (Table E4 ) (Video 1).
DISCUSSION
The principal finding of this study is that serum ferritin, transferrin saturation, and urine hepcidin-25 are each predictors of subsequent AKI development. The independent association of lower serum ferritin, lower urine hepcidin-25, and elevated transferrin saturation with AKI suggests that different iron regulatory pathways may be activated in response to IRI to collectively mitigate the impact of catalytic iron release on CPB, which is known to be an inciting factor for AKI. 8, 9 It is notable that these intraoperative iron-binding proteins improved on preoperative clinical AKI prediction, and this discrimination improved further with the addition of urine hepcidin-25 at POD 1; each preceded clinical AKI detection using serum Cr. Therefore, these data also suggest that intraoperative detection of incipient AKI may be feasible using readily available clinical assays.
Ferritin is an iron-binding protein found in intracellular and extracellular compartments and is capable of sequestering up to 4500 iron atoms intracellularly until required for metabolic processes. 23 Furthermore, ferritin is composed of H and L subunits that play a role in converting the oxidative state of reactive ferrous iron (Fe 2þ ) to the ferric form (Fe 3þ ), via ferroxidase activity. 24 In a pilot study (n ¼ 30), Davis and colleagues 25 demonstrated that lower preoperative serum ferritin was associated with increased AKI development, but these findings were not confirmed in a larger prospective observational cohort study (n ¼ 120). 26 Conversely, Leaf and colleagues 11 found that increased serum ferritin on POD 1 is associated with dialysis requirement or death. We expanded these findings by demonstrating that low intraoperative serum ferritin and elevated transferrin saturation are independent predictors for AKI during the initiation phase of IRI and speculate that the kinetics of ferritin elevation observed by Leaf and colleagues on POD 1 reflects an acute phase response concurrent with the extension phase of AKI. 11, 27, 28 Although it is possible that changes in intraoperative ferritin reflect an acute phase response, 29 it is unlikely to explain our findings because increased intraoperative ferritin was observed in patients without AKI, whereas increased inflammation would have been anticipated in patients with AKI.
Transferrin is an iron-binding transport protein, and under physiologic conditions approximately 30% of its binding sites are occupied. Transferrin saturation increases with elevated iron levels as additional binding Values expressed as median (interquartile range) or frequency (percent). eGFR calculated using the Modification of Diet in Renal Disease equation. AKI, Acute kidney injury; eGFR, estimated glomerular filtration rate; Cr, creatinine; CABG, coronary bypass graft; RBC, red blood cell; CPB, cardiopulmonary bypass; TIBC, total iron-binding capacity.
sites become occupied. We anticipated that transferrin saturation would increase between the start and 1 hour on CPB as free iron is released during CPB 11,30 ; however, this was not the case. This 1-hour window may have been insufficient to observe a significant increase in transferrin saturation, and indeed peak catalytic iron release has been observed at the end of CPB. 11 Nevertheless, increased transferrin saturation was an independent predictor for AKI development, and this may reflect an early adaptive response to minimize the effects of IRI by sequestering free iron. 10 Urine hepcidin-25 was inversely associated and an independent predictor of AKI. 15, 16, 31, 32 Urine hepcidin-25 was evaluated at POD 1, because it has been shown to have low intraoperative levels. 15, 16 Hepcidin-25 indirectly regulates circulating iron by degrading ferroportin, the only known iron exporter located predominantly on hepatocytes, macrophages, and enterocytes. 33 Because of the inverse association of urinary hepcidin-25 and the development of postcardiac surgery AKI, we have speculated that it is an endogenous renoprotective mechanism through sequestering catalytic free iron release during CPB. 15, 16, 34 Exogenously administered hepcidin has been shown to be highly protective in murine models of renal IRI and hemoglobin-mediated AKI, with a significant reduction in tubular injury, apoptosis, renal oxidative stress, and inflammation, and improved renal function. 8, 9 Notably, Scindia and colleagues 8 observed that renal IRI increased serum iron and hepcidin levels independently of surgery, and this effect was mitigated by pretreatment with hepcidin. These data suggest that hepcidin is increased secondary to iron homeostatic changes during IRI and is not strictly an inflammatory response to cardiac surgery.
Renal IRI alone results in elevated free iron levels, 8, 35 and this is further exacerbated during CPB, which can weaken RBC structural integrity, increasing plasma free hemoglobin and catalytic iron release. 11, 30 Intraoperative transfusion of older blood with an RBC storage lesion can further contribute to hemolysis and elevated free iron. 36 Indeed, older RBC transfusions are significantly associated with an increased risk of AKI after cardiac surgery. 37 Of note, we found that RBC transfusions and CPB pump time were not significant independent predictors of AKI after accounting for serum ferritin and transferrin saturation. Unfortunately, we did not have data on the duration of RBC storage before transfusion to delineate the effect of the RBC storage lesion on AKI development in this cohort. 37 Tight iron regulation within a homeostatic range is critical, because there are no active excretion mechanisms for excess iron. 24 Catalytic iron plays a key role in AKI development because it can participate in redox reactions to generate highly reactive hydroxyl radicals capable of oxidative damage and tubular lipid peroxidation, 35 and it has been shown to be nephrotoxic in murine models of IRI, 35 rhabdomyolysis, 38 and hemoglobinuria. 39 Ferroptosis is an iron-dependent form of regulated cell death that is characterized by tubular lipid peroxidation. 40 Ferroptosis plays a key role during renal IRI and other animal models of AKI, 10, 41 and heme oxygenase-1 is an endogenous ferroptosis inhibitor of renal proximal tubular epithelial cell death. 42 Taken together, we speculate that the observed elevated ferritin and hepcidin-25, with lower transferrin saturation, in patients without AKI reflect an increased capacity to sequester iron to help mitigate the effects of catalytic iron release during initiation of AKI. The eGFR calculated using the Modification of Diet in Renal Disease equation. OR, Odds ratio; AKI, acute kidney injury; CI, confidence interval; eGFR, estimated glomerular filtration rate; Cr, creatinine; CABG, coronary artery bypass grafting; RBC, red blood cell; CPB, cardiopulmonary bypass; TIBC, total iron-binding capacity. *Time (per 60 minutes). yIntraoperative urine output (per 100 mL). zSerum ferritin (per 100 mg/L). xTransferrin saturation (per 10%). kUrine hepcidin-25 (per 1000 mg/L). {Urine hepcidin-25:Cr (per 100 mg/mmoL).
mechanism by which this renoprotective effect occurs may be mediated through inhibition of ferroptosis ( Figure 3 ). Taken together, these findings support the importance of effective iron homeostatic mechanisms during CPB to rapidly adapt to a catalytic iron load. Our study has potential clinical and research implications. Understanding the significant and modifiable factors in cardiac surgery-associated AKI offers insight into potential risk mitigation approaches. First, restrictive transfusion strategies have been demonstrated to be noninferior to liberal transfusion strategies for cardiac surgery. 43, 44 This suggests that a restrictive transfusion strategy may be optimal for renal outcomes after cardiac surgery, given its demonstrated safety and as an approach to limit catalytic free iron release. 43, 44 Second, our data highlight the importance of iron-binding or sequestration as an independent and potentially modifiable risk in human AKI. This suggests the intriguing possibility that extracorporeal removal of free iron during CPB may be useful to protect against AKI. Food and Drug Administration-approved cartridges with immobilized deferoxamine have been developed for use in series with dialysis to maximize the intra-dialytic removal of iron and aluminum 45 and are effective for clearing nontransferrin bound iron, 46 and it is possible that these cartridges could be used in series with the CPB circuit. Although AKI pathophysiology is highly multifactorial in nature, targeted and minimally invasive interventions such as these may help to mitigate the effects of renal IRI.
Study Strengths and Limitations
Our study has several important strengths, including a rigorous prospective observational design, prospective and . Early intraoperative iron-binding proteins and postoperative iron-sequestering proteins may be endogenous renoprotective strategies that act to mitigate the impact of catalytic free iron release during CPB (top). The importance of maintaining iron homeostasis during cardiac surgery highlights the potential for minimally invasive, intraoperative AKI prevention strategies, and novel AKI therapeutics targeting these pathways (bottom). NGAL, Neutrophil gelatinase-associated lipocalin; IRI, ischemia-reperfusion injury; CPB, cardiopulmonary bypass; AKI, acute kidney injury.
systematic intraoperative serum sampling, careful clinical characterization, and the use of a well-validated outcome definition for AKI. Our study also has some limitations that we acknowledge. Because this is a single-center observational cohort, validation in independent cohorts will be required. Our cohort included patients with low to intermediate Thakar scores (average 3 [2] [3] [4] [5] for AKI and 2 [1] [2] [3] for patients without AKI). As such, we observed low rates of severe AKI and renal replacement therapy. Therefore, our results should be validated in higher-risk cohorts. These milder AKI phenotypes may have contributed to the modest intraoperative discrimination for postoperative AKI (AUC, 0.76). Nevertheless, these iron-binding proteins still outperformed previously reported intraoperative urine and plasma biomarker prediction for postoperative AKI. 6 Finally, although these observational data led us to speculate that changes in serum ferritin, transferrin saturation, and hepcidin-25 identify distinct iron homeostatic mechanisms that may be renoprotective in human IRI, we cannot prove causation.
CONCLUSIONS
This study demonstrates that intraoperative serum ferritin and transferrin saturation are independently associated with the development of postoperative cardiac surgery AKI. Because serum ferritin, transferrin saturation, and urine hepcidin-25 are each independent predictors of AKI, this suggests that iron sequestration is a key and potentially modifiable factor in AKI. These data may help inform targeted and minimally invasive AKI prevention strategies. Clinical trials ultimately will be required to evaluate specific AKI interventions, and these data may be useful as an enrichment strategy to recruit patients at high risk of developing AKI. Indeed, early intraoperative detection of incipient AKI may be feasible using Food and Drug Administration-validated quantitative assays for serum ferritin and transferrin saturation, which are readily available in clinical laboratories. 
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